Some inhibitors of CDK4/6 have been approved for use in combination with nonsteroidal aromatase inhibitors for the first-line treatment of breast cancer in postmenopausal women, and PFS can be increased by 40-45% [39, 40]. Here, CDK4 is linked to breast carcinoma.